Johnson & Johnson has made history by surpassing $100 billion in annual sales for the first time, driven by a 9.1% year-over-year increase and a significant 20.6% rise in adjusted earnings per share to $2.46. This achievement has attracted analyst attention, notably prompting Morgan Stanley to upgrade its rating from 'Equal-Weight' to 'Overweight' while raising the price target from $200 to $262 per share. Despite facing challenges such as patent expirations, projections indicate continued revenue and earnings growth through 2030, bolstering investor confidence.
“Joaquin Duato · sold · shares · 100,000 shares at an average price of $221.23 per share, for a total value of $22.12M”
“Joaquin Duato · holds · shares · 307,807 shares”
“Manish Bhatia · sold · shares · 26,623 shares in the price range of $388.78 to $395.87 per share, totaling $10.41M”
“Manish Bhatia · holds · shares · 323,486 shares”
“Carey Halio · sold · shares · 2,846 shares in the price range of $921.25 to $932.81 per share, for a total value of $2.64M”
“Carey Halio · holds · shares · 2,017 shares”
“David Solomon · sold · shares · 272 shares at an average price of $938.92 per share, totaling $255,387”
“David Solomon · holds · shares · 141,698 shares”
“Daniel Simkowitz · sold · shares · 32,968 shares at an average price of $182.61 per share, for a total value of $6.02M”
“Daniel Simkowitz · holds · shares · 359,137 shares”
“Margaret Banks · sold · shares · 2,600 shares at an average price of $34.18 per share, totaling $88,855”
“Margaret Banks · holds · shares · 14,043 shares”
.svg&width=160)
